4507:TYO
Shionogi & Co Ltd
2 744,50 JPY
arrow_downward
-0,88%(-24,50) 1D
9 ოქტ, 15:30:00 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
2 758 JPY
High
2 778 JPY
Low
2 734 JPY
Mkt. cap
2,44 ტრლ.
Avg. vol.
2,93 მლნ.
Volume
3,31 მლნ.
Dividend
2,59%
Quarterly dividend
18 JPY
Ex-dividend date
29 სექ. 2026
P/E ratio
8,86
52-wk high
3 758 JPY
52-wk low
2 392 JPY
EPS
310 JPY
Shares outstanding
314,50 მლნ.
No. of employees
6 ათ.
Open
2 758 JPY
High
2 778 JPY
Low
2 734 JPY
Mkt. cap
2,44 ტრლ.
Avg. vol.
2,93 მლნ.
Volume
3,31 მლნ.
Dividend
2,59%
Quarterly dividend
18 JPY
Ex-dividend date
29 სექ. 2026
P/E ratio
8,86
52-wk high
3 758 JPY
52-wk low
2 392 JPY
EPS
310 JPY
Shares outstanding
314,50 მლნ.
No. of employees
6 ათ.
News stories
From web sources and news partners
Yahoo Finance UK
·
1 დღის წინ
Shionogi (TSE:4507) Weighs IntraBio Acquisition, Is The Stock A Bargain?
Simply Wall Street
·
1 დღის წინ
Shionogi (TSE:4507) Weighs IntraBio Deal, Is The Stock Undervalued?
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi & Co Ltd
CEOისაო ტესიროგი
Employees6,22 ათ.
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com